Table 1: Acute vascular neurological manifestation in patients with SARV-CoV-2 infection.
Study |
Patients |
Age |
Gender |
UD |
D-dimer |
Type of stroke |
Treatment |
Outcome |
Avula, et al. [6] |
4 |
81* |
75%, F 25%, M |
Hypertension: 100% Dyslipdemia: 75% Diabetes: 25% |
Elevated: 50% |
IS |
Aspirin |
75% died |
Saiegh, et al. [7] |
2 |
46.5* |
50%, F 50%, M |
None: 50% ns: 50% |
ns |
IS ICH |
External ventricular drain and specific surgery |
Survive |
Beyrouti, et al. [8] |
6 |
69.8* |
33.3%, F 66.6%, M |
Hypertension: 66.6% |
Elevated: 100% |
IS |
Anticoagulation: 66.6% Intravenous thrombolysis: 16.6% |
16.6% died |
González- Pinto, et al. [9] |
1 |
36 |
F |
ns |
Elevated |
IS |
Supportive Measures |
Survive |
Oxley, et al. [10] |
5 |
40.4* |
20%, F 80%, M |
Hypertension: 20% Dyslipdemia: 20% Diabetes: 40% |
Elevated: 60% |
IS |
Aspirin: 60% Clot retrieval: 80% Intravenous thrombolysis: 20% Anticoagulation: 40% |
Survive |
Moshayei, et al. [11] |
1 |
80 |
M |
Heart failure, cardiovascular shock, and ischemic bilateral lower limbs |
ns |
IS |
Supportive measures |
Survive |
Hughes, et al. [12] |
1 |
59 |
F |
ns |
ns |
CVST |
LMWH |
Survive |
Viguier, et al. [13] |
1 |
73 |
M |
ns |
Elevated |
IS |
LMWH |
Survive |
Tunç, et al. [14] |
4 |
65.3* |
50% M 50% F |
Diabetes: 25% Hypertension: 75% |
Elevated: 75% |
IS |
Antithrombotic therapy |
Survive |
Goldberg, et al. [15] |
1 |
64 |
M |
Hypertension, aplastic anemia, and splenectomy |
Elevated |
IS |
ns |
ns |
*Median; F: female; M: male; y: years; UD: underlying disorders; IS: ischemic stroke; ICH: intracerebral hemorrhage; CVST: cerebral venous sinus thrombosis; ns: not specified; LMWH: low molecular weight heparin; D-dimer elevated levels: > 250 ng/ml.